Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes.
Academic Article
Publication Date:
2014
Iris type:
1.1 Articolo in rivista
List of contributors:
Aronson, R; Gottlieb, Pa; Christiansen, Js; Donner, Tw; Bosi, Emanuele; Bode, Bw; Pozzilli, P.
Published in: